Zhimu-Huangbai herb-pair ameliorates hepatic steatosis in mice by regulating IRE1α/XBP1s pathway to inhibit SREBP-1c

Phytomedicine. 2024 Nov:134:156017. doi: 10.1016/j.phymed.2024.156017. Epub 2024 Sep 2.

Abstract

Background: Currently, there is a lack of validated pharmacological interventions for non-alcoholic fatty liver disease (NAFLD), which is characterized by the accumulation of hepatic triglyceride. Zhimu-Huangbai (ZH) herb-pair is a traditional Chinese medicine that regulates glucose and lipid metabolism disorders. However, the precise mechanisms underlying the preventive effects of hepatic triglyceride induced by high-fat diet (HFD) remain elusive.

Purpose: The study aimed to examine the impact of ZH herb-pair on NAFLD in mice and explore the underlying mechanisms, particularly its effects on endoplasmic reticulum (ER) stress and lipid metabolism.

Methods: NAFLD was induced in mice using HFD, and the treated mice were orally administered ZH, metformin (Glucophage) or lovastatin. The lipid metabolism factors, ER stress markers, and the unfolded protein response (UPR) branch factors were measured using immunohistochemistry, western blotting or qRT-PCR. Co-Immunoprecipitation (CoIP) was performed to reveal the connection between SCAP and SREBP-1c. Tunicamycin (TM) and plasmid delivery were used to induce acute ER stress or crease XBP1 gain function models. The main compounds in ZH binding to IRE1α protein were studied by molecular docking and cellular thermal shift assay (CETSA).

Results: Treatment with ZH significantly ameliorated hepatic steatosis and reduced lipid synthesis process mainly inhibiting the expression of mature active form of SREBP-1c through relieving ER stress. The expression of IRE1α and XBP1s was inhibited after treatment with ZH. In addition, ZH improved the fatty liver phenotype caused by XBP1 overexpression via decreasing srebp1c transcription. In vitro experimental results suggested that the main compounds in ZH decreased cellular TG contents. Mechanistically, ZH targeted IRE1α and inhibited XBP1s mRNA expression to relieve ER stress and inhibit SREBP-1c production.

Conclusions: ZH herb-pair can protect against NAFLD by reducing the expression of SREBP-1c, in part, via regulating IRE1α/XBP1s pathway.

Keywords: Endoplasmic reticulum stress; IRE1α/XBP1s pathway; Non-alcoholic fatty liver disease; SREBP-1c; Zhimu-Huangbai herb-pairs.

MeSH terms

  • Animals
  • Diet, High-Fat / adverse effects
  • Drugs, Chinese Herbal* / pharmacology
  • Endoplasmic Reticulum Stress* / drug effects
  • Endoribonucleases* / metabolism
  • Humans
  • Lipid Metabolism / drug effects
  • Liver / drug effects
  • Liver / metabolism
  • Lovastatin / pharmacology
  • Male
  • Metformin / pharmacology
  • Mice
  • Mice, Inbred C57BL
  • Non-alcoholic Fatty Liver Disease* / drug therapy
  • Protein Serine-Threonine Kinases* / metabolism
  • Signal Transduction / drug effects
  • Sterol Regulatory Element Binding Protein 1 / metabolism
  • Triglycerides / metabolism
  • Unfolded Protein Response / drug effects
  • X-Box Binding Protein 1 / metabolism

Substances

  • Drugs, Chinese Herbal
  • Endoribonucleases
  • Ern1 protein, mouse
  • Lovastatin
  • Metformin
  • Protein Serine-Threonine Kinases
  • Srebf1 protein, mouse
  • Sterol Regulatory Element Binding Protein 1
  • Triglycerides
  • X-Box Binding Protein 1
  • Xbp1 protein, mouse